Literature DB >> 31570395

Activity of a novel 1,3-beta-D-glucan Synthase Inhibitor, Ibrexafungerp (formerly SCY-078), Against Candida glabrata.

M Ghannoum1, L Long2, N Isham2, C Hager2, R Wilson2, K Borroto-Esoda3, S Barat3, D Angulo3.   

Abstract

Ibrexafungerp (formerly SCY-078), a novel glucan synthase inhibitor with oral availability, was evaluated for activity against Candida glabrata Susceptibility of clinical strains to Ibrexafungerp was determined by microdilution and time kill assays. The MIC range against wild type strains was 1-2 μg/mL. IBX was also active against the majority of echinocandin-resistant strains. Time kill studies showed a 4 to 6-log reduction in growth at concentrations of 0.25 to 4 μg/ml at 24 and 48 hr.
Copyright © 2019 American Society for Microbiology.

Entities:  

Year:  2019        PMID： 31570395      PMCID： PMC6879250          DOI： 10.1128/AAC.01510-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Breakthrough invasive candidiasis in patients on micafungin.

Authors:  Christopher D Pfeiffer; Guillermo Garcia-Effron; Aimee K Zaas; John R Perfect; David S Perlin; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

2.  Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates.

Authors:  Cristina Jiménez-Ortigosa; Padmaja Paderu; Mary R Motyl; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

3.  Novel FKS mutations associated with echinocandin resistance in Candida species.

Authors:  Guillermo Garcia-Effron; Daniel Joseph Chua; Jon Rupert Tomada; Joseph DiPersio; David S Perlin; Mahmoud Ghannoum; Hector Bonilla
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

4.  Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods.

Authors:  M E Klepser; E J Ernst; R E Lewis; M E Ernst; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species.

Authors:  Wiley A Schell; A M Jones; Katyna Borroto-Esoda; Barbara D Alexander
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

6.  Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.

Authors:  Michael A Pfaller; Shawn A Messer; Paul R Rhomberg; Katyna Borroto-Esoda; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

7.  The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp.

Authors:  Laura Judith Marcos-Zambrano; Marta Gómez-Perosanz; Pilar Escribano; Emilio Bouza; Jesús Guinea
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

8.  Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST).

Authors:  Michael A Pfaller; Shawn A Messer; Mary R Motyl; Ronald N Jones; Mariana Castanheira
Journal:  J Antimicrob Chemother       Date:  2012-11-28       Impact factor: 5.790
  8 in total
  10 in total

1.  Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model.

Authors:  Annie Lee; Brendan Prideaux; Matthew Zimmerman; Claire Carter; Stephen Barat; David Angulo; Véronique Dartois; David S Perlin; Yanan Zhao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vivo Activity in a Murine Model of Hematogenously Disseminated Candida albicans.

Authors:  Sherman Chu; Lisa Long; Thomas S McCormick; Katyna Borroto-Esoda; Stephen Barat; Mahmoud A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

3.  Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.

Authors:  Martin Hoenigl; Rosanne Sprute; Amir Arastehfar; John R Perfect; Cornelia Lass-Flörl; Romuald Bellmann; Juergen Prattes; George R Thompson; Nathan P Wiederhold; Mohanad M Al Obaidi; Birgit Willinger; Maiken C Arendrup; Philipp Koehler; Matteo Oliverio; Matthias Egger; Ilan S Schwartz; Oliver A Cornely; Peter G Pappas; Robert Krause
Journal:  Expert Opin Investig Drugs       Date:  2022-06-15       Impact factor: 6.498

Review 4.  Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections.

Authors:  Mahmoud Ghannoum; Maiken Cavling Arendrup; Vishnu P Chaturvedi; Shawn R Lockhart; Thomas S McCormick; Sudha Chaturvedi; Elizabeth L Berkow; Deven Juneja; Bansidhar Tarai; Nkechi Azie; David Angulo; Thomas J Walsh
Journal:  Antibiotics (Basel)       Date:  2020-08-25

5.  Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Aspasia Katragkou; Bo Bo Win Maung; Ethan Naing; Povilas Kavaliauskas; Stephen Barat; Katyna Borroto-Esoda; Nkechi Azie; David Angulo; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

Review 6.  Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor.

Authors:  Sabelle Jallow; Nelesh P Govender
Journal:  J Fungi (Basel)       Date:  2021-02-25

Review 7.  Novel antifungal agents in clinical trials.

Authors:  Samantha E Jacobs; Panagiotis Zagaliotis; Thomas J Walsh
Journal:  F1000Res       Date:  2021-06-28

Review 8.  The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.

Authors:  Martin Hoenigl; Rosanne Sprute; Matthias Egger; Amir Arastehfar; Oliver A Cornely; Robert Krause; Cornelia Lass-Flörl; Juergen Prattes; Andrej Spec; George R Thompson; Nathan Wiederhold; Jeffrey D Jenks
Journal:  Drugs       Date:  2021-10-09       Impact factor: 9.546

Review 9.  Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents.

Authors:  Nathan P Wiederhold
Journal:  J Fungi (Basel)       Date:  2022-08-16

Review 10.  Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata.

Authors:  Ahmed Gamal; Sherman Chu; Thomas S McCormick; Katyna Borroto-Esoda; David Angulo; Mahmoud A Ghannoum
Journal:  Front Cell Infect Microbiol       Date:  2021-03-11       Impact factor: 5.293
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.